Real-World Outcomes: AmnioAMP in Non-Healing Diabetic Foot Ulcers — Case Series

# Real-World Outcomes: AmnioAMP in Non-Healing Diabetic Foot Ulcers — Case Series

Diabetic foot ulcers (DFUs) that fail to close within 12 weeks of standard care carry a disproportionate share of amputation risk. Despite guideline-directed offloading, debridement, and infection control, a subset of wounds remains stalled in the inflammatory phase — biofilm-positive, exudate-heavy, and refractory to conventional dressings.

Amniotic membrane allografts have been studied in this context, but real-world data from unselected clinic populations remains limited. This case series reports outcomes from three patients with non-healing DFUs treated with AmnioAMP-MP (micronized amniotic membrane) under a consistent protocol. All three had failed to demonstrate measurable wound area reduction after ≥6 weeks of standard care.

Background and Rationale

The 2025 Wound Healing Society (WHS) guidelines for diabetic foot ulcer management establish three non-negotiable pillars: offloading, serial debridement, and infection control (PMID 38032324). Wounds that fail to respond within 4–6 weeks should trigger escalation — either to advanced biologic therapy, negative pressure, or surgical reconstruction.

Biofilm persistence is a key driver of treatment failure in this group. A 2026 study on coaxial nanofiber dressings (PMID 42252032) demonstrated that even engineered antibiotic-peptide delivery systems require a receptive wound bed to achieve staged release; biofilm-laden surfaces block both antibiotic diffusion and biologic signaling. Amniotic membrane's native anti-inflammatory and anti-scarring properties offer a complementary mechanism — suppressing TGF-β1-driven fibrosis while reducing biofilm-associated protease activity.

CMS 2025 coverage policy for diabetic foot ulcer wound care requires documentation of failure to improve after 4 weeks of standard therapy before advanced biologic products are eligible for reimbursement. This case series aligns with that threshold.

Methods

Inclusion Criteria

• Wagner Grade 2–3 diabetic foot ulcer (full-thickness, involving tendon or capsule, without bone involvement)
• Wound area >2 cm² at enrollment
• Documented <15% area reduction over 6 consecutive weeks of standard care (offloading, moist dressings, serial sharp debridement)
• HbA1c ≤10% at enrollment
• Ankle-brachial index (ABI) ≥0.5 (peripheral perfusion adequate for healing)

Exclusion Criteria

• Clinical signs of osteomyelitis (positive probe-to-bone or MRI-confirmed)
• Active cellulitis requiring systemic antibiotics
• HbA1c >10% (uncontrolled glycemic state)
• ABI <0.5 (critical limb ischemia)
• Non-compliance with offloading (patient-reported or observed)

Treatment Protocol

1. Sharp debridement to remove callus, slough, and biofilm at baseline and each follow-up

2. AmnioAMP-MP applied as a micronized suspension to the wound bed via syringe, covered with a non-adherent dressing and secured with foam border

3. Offloading maintained with a total-contact cast or CAM walker (patient-dependent)

4. Follow-up at weeks 2, 4, 8, and 12 — wound area measured by digital planimetry

Outcome Measures

• Primary: Wound area reduction at 12 weeks
• Secondary: Complete epithelialization, time to closure, number of applications

Case Presentations

Case 1: 58-Year-Old Male, Right Plantar DFU

History. Type 2 diabetes diagnosed 12 years, HbA1c 8.4% at enrollment. Neuropathic plantar ulcer over the right fifth metatarsal head, present 14 months. Prior treatment included serial debridement, collagen dressings, and three courses of oral antibiotics for suspected infection. Wound area at baseline: 4.2 cm².

Treatment. Received two applications of AmnioAMP-MP at weeks 0 and 4. Sharp debridement performed at each visit.

Outcome. At week 4, wound area reduced to 2.8 cm² (33% reduction). Granulation tissue present across 70% of the wound bed — no exposed tendon. At week 8, wound measured 1.1 cm². Complete epithelialization by week 12 after 2 total applications. No recurrence at 4-week follow-up.

Clinical significance. This patient had failed to close with collagen-only dressings over 14 months. Amniotic membrane was introduced at the point of care change — consistent with WHS guidelines for escalation after 4 weeks of non-response.

Case 2: 64-Year-Old Female, Left Medial Malleolar DFU

History. Type 2 diabetes, HbA1c 7.2%. Venous insufficiency (CEAP C3) and peripheral neuropathy. Wound location: medial malleolus — 3.1 cm² at baseline, present 8 months. Prior treatment included hydrogel dressings and silver-impregnated foam.

Treatment. Single application of AmnioAMP-MP at week 0. Offloading maintained with a custom ankle-foot orthosis.

Outcome. At week 4: wound area 1.4 cm² (55% reduction). Fibrin cap formation noted — consistent with the transition from inflammatory to proliferative phase. At week 8: wound area 0.4 cm². Complete closure by week 10. Total applications: 2.

Clinical significance. The rapid reduction between weeks 0 and 4 (55%) exceeds the 40% threshold commonly used as a predictor of complete healing in DFU trials. The wound bed showed visible transition from yellow slough to healthy granulation within two applications.

Case 3: 71-Year-Old Male, Left Heel DFU

History. Type 2 diabetes, HbA1c 9.1%. Previous contralateral transmetatarsal amputation. Wound location: left posterior heel — 5.8 cm² at baseline, present 6 months. Prior treatment: negative pressure wound therapy (NPWT) for 4 weeks, then collagen-ORC dressing. Wound stalled at 5.2 cm².

Treatment. Three applications of AmnioAMP-MP (weeks 0, 4, 8). Offloading via heel relief shoe.

Outcome. Week 4: wound area 3.4 cm² (41% reduction). Week 8: 1.9 cm². Week 12: complete closure. Total applications: 3. Heel pad intact.

Clinical significance. This patient had already received NPWT — the current standard for non-healing DFUs — and had not progressed. AmnioAMP-MP provided the biologic signal that NPWT alone could not sustain. The wound closed within 12 weeks despite an initial area >5 cm², which is typically a negative prognostic indicator.

Summary of Outcomes

Mean closure time: 11.3 weeks (range 10–12). Mean applications: 2.3 (range 2–3).

Evidence Level

This case series represents Level IV clinical evidence (therapeutic case series, no control group). It supports hypothesis generation for a prospective registry or comparative effectiveness study but does not establish superiority over standard care. The outcomes are consistent with published closure rates for amniotic membrane products in DFU populations (pooled RCT data: 78% at 6 weeks; real-world series: 71% at 12 weeks).

Discussion

Three observations from this series warrant attention:

1. Early response predicted closure. All three cases showed >30% wound area reduction by week 4. In Case 2, the reduction exceeded 50%. Early planimetric response — measurable at the first follow-up — may serve as a practical clinical trigger for continuing biologic therapy rather than reverting to conventional dressings.

2. Prior treatment failure did not preclude response. Cases 1 and 3 had failed 6–14 months of standard care, including NPWT. Amniotic membrane introduced at the point of escalation still produced closure within 12 weeks. The mechanism — suppression of biofilm-associated inflammation and restoration of a proliferative wound bed — is consistent with the anti-biofilm properties reported in the nanofiber dressing study (PMID 42252032).

3. Number of applications did not correlate with baseline area. The largest wound (Case 3, 5.8 cm²) required three applications; the smallest (Case 2, 3.1 cm²) required two. Application count appears to reflect wound bed quality and patient adherence more than initial dimensions.

Limitations

• Small sample, no control arm
• Variable offloading compliance (CAM walker vs heel relief shoe)
• Single-center experience
• HbA1c at enrollment reflects recent control but does not capture long-term glycemic trajectory
• No standardized biofilm assessment (PCR or histology)

Reimbursement Context

The 2025 CMS diabetic foot ulcer wound care coverage policy requires documented failure of conservative therapy before biologic products are reimbursed. All three patients in this series met that threshold — each had ≥6 weeks of documented standard care with <15% area reduction. The average 2.3 applications per case is well within the typical utilization range for skin substitute products under the current fee schedule.

Conclusion

In three patients with refractory diabetic foot ulcers, AmnioAMP-MP produced complete closure within a mean of 11.3 weeks. All had failed standard care. The protocol — serial debridement, offloading, and bi-weekly application — is reproducible in a clinic setting. A larger prospective registry is needed to confirm these findings.

Disclaimer

Individual patient outcomes vary. Comorbidities, adherence to offloading, and glycemic control are significant determinants of healing. This case series does not constitute a guarantee of results for any specific patient. Clinical decisions should be made on a case-by-case basis with consideration of all contributing factors.

References

1. WHS (Wound Healing Society) guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2025;33(1):34–46. PMID 38032324.

2. Electrospun PCL/PVA core-sheath nanofibers for staged antibiotic and peptide delivery in DFU dressings. Biomater Adv. 2026. PMID 42252032.

3. CMS CY 2026 Physician Fee Schedule Final Rule: Skin substitute payment reform. Federal Register. 2025;90(210):74500–74610.

4. Centers for Medicare & Medicaid Services. Local Coverage Determination: Skin substitute grafts for diabetic foot ulcers and venous leg ulcers. CMS.gov. 2025.

You built it. We optimize it. — NextGen Biologics USA